EMERGENT BIOSOLUTIONS INC. Proceeds from Issuance of Warrants
EMERGENT BIOSOLUTIONS INC. (EBS) reported Proceeds from Issuance of Warrants of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2026-02-27
- EMERGENT BIOSOLUTIONS INC. proceeds from issuance of warrants for the quarter ending 2025-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from issuance of warrants for the quarter ending 2024-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from issuance of warrants for the quarter ending 2023-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from issuance of warrants for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. proceeds from issuance of warrants for fiscal 2024 was $13.40M.
- EMERGENT BIOSOLUTIONS INC. proceeds from issuance of warrants for fiscal 2023 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from issuance of warrants for fiscal 2022 was $0.00.
| Period end | Proceeds from Issuance of Warrants 3 month | Proceeds from Issuance of Warrants 9 month | Proceeds from Issuance of Warrants 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-30 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $13.40M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $13.40M 10-Q · filed 2025-10-30 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |